PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

131 articles indexed across 16 specialties, each reviewed by a licensed pharmacist before publication.

⭐ Featured free samples

Three of our best full deep-analysis reports: hand-picked, free to read in full, no subscription required.

🔓 Free Sample
Nephrology / Renal Pharmacy ConfirmatoryGrade: Moderate

Finerenone Outperforms Spironolactone for Cardiorenal Protection in Moderate CKD

American journal of cardiovascular drugs : drugs, devices, and other interventions · Jul 20, 2026

Finerenone emerges as the safer choice for CKD patients.

Read Free →
🔓 Free Sample
Neurology / Neuropharmacology ConfirmatoryGrade: Low

Tenecteplase Shortens Stroke Treatment and Transfer Times

JAMA network open · Jul 13, 2026

Tenecteplase speeds up stroke thrombolysis compared to alteplase.

Read Free →
🔓 Free Sample
Rheumatology / Immunology ConfirmatoryGrade: Moderate

EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations

Annals of the rheumatic diseases · Jun 13, 2026

New EULAR guidelines redefine RA management with DMARDs.

Read Free →
Showing 5 from 1 topic.Sort: Newest | Oldest
EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations
🔓 Free Teaser Rheumatology / Immunology Confirmatory Grade: Moderate
Smolen JS, Edwards CJ, Konzett V, et al.
📅 Jun 13, 2026 · Annals of the rheumatic diseases

New EULAR guidelines redefine RA management with DMARDs.

Dupilumab After JAK Inhibitor Withdrawal: Small Real-World Signal
Rheumatology / Immunology Hypothesis-generating Grade: Very Low
Wang Q, Yang G, Li Y, et al.
📅 Jul 16, 2026 · Frontiers in immunology

Switching from JAK inhibitors to dupilumab shows promise in atopic dermatitis management.

JAK Inhibitors Show Limited Efficacy in Refractory JIA Uveitis
Rheumatology / Immunology Hypothesis-generating Grade: Very Low
Baquet-Walscheid K, Wortmann C, Rothaus K, et al.
📅 Jul 11, 2026 · Pediatric rheumatology online journal

Janus kinase inhibitors show limited efficacy in JIA-associated uveitis.

2025 ACR SLE Guideline Prioritizes Hydroxychloroquine and Glucocorticoid Minimization
Rheumatology / Immunology Practice-changing Grade: Low
Sammaritano LR, Askanase A, Bermas BL, et al.
📅 Jul 4, 2026 · Arthritis & rheumatology (Hoboken, N.J.)

New guidelines unify SLE treatment strategies for better outcomes.

Obinutuzumab Improves Response in Active Non-Renal SLE
Rheumatology / Immunology Practice-changing Grade: High
Furie RA, Dall'Era M, Vital EM, et al.
📅 Mar 6, 2026 · N Engl J Med

Obinutuzumab improves SLE outcomes in the recent ALLEGORY trial.